Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Center, Extension Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With or Without Ribavirin, for an Additional 36 Weeks

NCT00292084 is registered in ClinicalTrials.gov with BioWest Therapeutics Inc as lead sponsor.

NCT NCT00292084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00292084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Center, Extension Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With or Without Ribavirin, for an Additional 36 Weeks
Lead sponsor
BioWest Therapeutics Inc
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
October 31, 2007
Enrollment
60
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic